An evolving approach to anemia management in chronic kidney disease emphasizes individualized, stage-specific care with a focus on early detection and risk-based treatment strategies. Correction of iron deficiency and underlying inflammation is prioritized before initiating or adjusting E therapy. Maintaining a safe hemoglobin target range is essential to balance therapeutic benefits and cardiovascular safety. Long-acting agents such as D are preferred due to less frequent dosing, improved patient adherence, and reduced variability in hemoglobin levels compared to short-acting options. Iron supplementation remains a foundational component, administered based on disease stage and patient tolerance. Newer therapeutic classes like H show potential but require close monitoring for safety. Overall, management aims to minimize transfusion needs and optimize long-term clinical outcomes through structured monitoring.^[1][2]